MedTrace Logo

Isoflavone in Prostate-specific Antigen Recurrent Prostate Cancer

NCT00596895 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2011-09-20

No results posted yet for this study

Summary

Primary Outcome Measures:

Decrease in rate of serum PSA rise

Secondary Outcome Measures:

Adherence to treatment regimens

Quality of life as assessed by FACT-P at baseline and at 12 months of treatment

Modulation of serum testosterone,isoflavone metabolites, and cholesterol

Estimated Enrollment: 27 Study Start Date: November 2003 Estimated Primary Completion Date: February 2007 (Final data collection date for primary outcome measure)

Conditions

  • Biochemical Recurrent Prostate Cancer

Interventions

DIETARY_SUPPLEMENT

Isoflavone

Ingested 47 mg of isoflavone in three 8 oz servings per day

Sponsors & Collaborators

  • University of Florida

    lead OTHER

Principal Investigators

  • Charles J. Rosser, MD · University of Florida

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
45 Years
Max Age
80 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-11-30
Primary Completion
2007-11-30
Completion
2007-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00596895 on ClinicalTrials.gov